{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,23]],"date-time":"2026-09-23T17:40:12Z","timestamp":1790185212078,"version":"4.1.0"},"reference-count":28,"publisher":"Ovid Technologies (Wolters Kluwer Health)","issue":"12","content-domain":{"domain":["lww.com","ovid.com"],"crossmark-restriction":true},"short-container-title":[],"published-print":{"date-parts":[[2020,12]]},"abstract":"<jats:sec>\n            <jats:title>Background.<\/jats:title>\n            <jats:p>Oral anticoagulation therapy is frequently prescribed to kidney transplant recipients (KTRs) for prevention and treatment of thrombotic events. Over the past 10 y, direct oral anticoagulants (DOACs) have shown similar efficacy with a safety profile equal or superior to that of vitamin K antagonist anticoagulants (VKAs) in the general population. However, little data are available on kidney transplantation.<\/jats:p>\n          <\/jats:sec>\n          <jats:sec>\n            <jats:title>Methods.<\/jats:title>\n            <jats:p>We investigated the efficacy (thrombotic events) and safety (hemorrhagic and other adverse events and graft outcomes) of DOACs in a cohort of KTRs with a renal function &gt;30\u2009mL\/min. We then compared these patients to a control group treated by VKA.<\/jats:p>\n          <\/jats:sec>\n          <jats:sec>\n            <jats:title>Results.<\/jats:title>\n            <jats:p>Fifty-two KTRs treated by DOACs between 2013 and 2018 at Necker Hospital were included. Patients were with a mean age of 62 \u00b1 13 y old and a mean glomerular filtration rate of 59 \u00b1 20\u2009mL\/min\/1.73m<jats:sup>2<\/jats:sup>. The major indication was atrial fibrillation (n = 31 [60%]). Apixaban was the most commonly used agent (n = 36 [69%]). No thrombotic complications were reported under DOAC until last follow-up (14.1 \u00b1 13 mo). In comparison to 50 controls under VKA during the same period, the bleeding rate under DOAC was significantly lower (11.5 versus 22.9 per 100 patient-y, <jats:italic toggle=\"yes\">P<\/jats:italic> = 0.037) with a hazard ratio of 0.39 (95% confidence interval, 0.19-0.85, <jats:italic toggle=\"yes\">P<\/jats:italic> = 0.041). No significant changes in kidney function, rejection rate, or hemoglobin level were reported.<\/jats:p>\n          <\/jats:sec>\n          <jats:sec>\n            <jats:title>Conclusions.<\/jats:title>\n            <jats:p>DOACs appear to be effective and safe anticoagulants in KTRs with stable renal function.<\/jats:p>\n          <\/jats:sec>","DOI":"10.1097\/tp.0000000000003168","type":"journal-article","created":{"date-parts":[[2020,2,12]],"date-time":"2020-02-12T20:30:55Z","timestamp":1581539455000},"page":"2625-2631","update-policy":"https:\/\/doi.org\/10.1097\/lww.0000000000001000","source":"Crossref","is-referenced-by-count":24,"title":["Efficacy and Safety of Direct Oral Anticoagulants in Kidney Transplantation: A Single-center Pilot Experience"],"prefix":"10.1097","volume":"104","author":[{"given":"Juliette","family":"Leon","sequence":"first","affiliation":[{"name":"Service de N\u00e9phrologie et Transplantation Adulte, H\u00f4pital Necker-Enfants Malades, Universit\u00e9 Paris Descartes, Assistance Publique-H\u00f4pitaux de Paris, Paris, France."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Laurent","family":"Sabbah","sequence":"additional","affiliation":[{"name":"Service de Cardiologie, H\u00f4pital Necker, Universit\u00e9 Paris Descartes, Assistance Publique-H\u00f4pitaux de Paris, Paris, France."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Olivier","family":"Aubert","sequence":"additional","affiliation":[{"name":"Service de N\u00e9phrologie et Transplantation Adulte, H\u00f4pital Necker-Enfants Malades, Universit\u00e9 Paris Descartes, Assistance Publique-H\u00f4pitaux de Paris, Paris, France."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Dany","family":"Anglicheau","sequence":"additional","affiliation":[{"name":"Service de N\u00e9phrologie et Transplantation Adulte, H\u00f4pital Necker-Enfants Malades, Universit\u00e9 Paris Descartes, Assistance Publique-H\u00f4pitaux de Paris, Paris, France."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xavier","family":"Delavenne","sequence":"additional","affiliation":[{"name":"Laboratoire de Pharmacologie-Toxicologie, Centre Hospitalier Universitaire, Saint-Etienne, France."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Julien","family":"Zuber","sequence":"additional","affiliation":[{"name":"Service de N\u00e9phrologie et Transplantation Adulte, H\u00f4pital Necker-Enfants Malades, Universit\u00e9 Paris Descartes, Assistance Publique-H\u00f4pitaux de Paris, Paris, France."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lucile","family":"Amrouche","sequence":"additional","affiliation":[{"name":"Service de N\u00e9phrologie et Transplantation Adulte, H\u00f4pital Necker-Enfants Malades, Universit\u00e9 Paris Descartes, Assistance Publique-H\u00f4pitaux de Paris, Paris, France."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Anne","family":"Scemla","sequence":"additional","affiliation":[{"name":"Service de N\u00e9phrologie et Transplantation Adulte, H\u00f4pital Necker-Enfants Malades, Universit\u00e9 Paris Descartes, Assistance Publique-H\u00f4pitaux de Paris, Paris, France."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Geltrude","family":"Giura","sequence":"additional","affiliation":[{"name":"Service de Cardiologie, H\u00f4pital Necker, Universit\u00e9 Paris Descartes, Assistance Publique-H\u00f4pitaux de Paris, Paris, France."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Gillian","family":"Divard","sequence":"additional","affiliation":[{"name":"Service de N\u00e9phrologie et Transplantation Adulte, H\u00f4pital Necker-Enfants Malades, Universit\u00e9 Paris Descartes, Assistance Publique-H\u00f4pitaux de Paris, Paris, France."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Christophe","family":"Legendre","sequence":"additional","affiliation":[{"name":"Service de N\u00e9phrologie et Transplantation Adulte, H\u00f4pital Necker-Enfants Malades, Universit\u00e9 Paris Descartes, Assistance Publique-H\u00f4pitaux de Paris, Paris, France."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Rebecca","family":"Sberro-Soussan","sequence":"additional","affiliation":[{"name":"Service de N\u00e9phrologie et Transplantation Adulte, H\u00f4pital Necker-Enfants Malades, Universit\u00e9 Paris Descartes, Assistance Publique-H\u00f4pitaux de Paris, Paris, France."}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"276","published-online":{"date-parts":[[2020,2,10]]},"reference":[{"key":"R1-20241210","doi-asserted-by":"crossref","first-page":"2893","DOI":"10.1093\/eurheartj\/ehw210","article-title":"2016 ESC guidelines for the management of atrial fibrillation developed in collaboration with EACTS.","volume":"37","author":"Kirchhof","year":"2016","journal-title":"Eur Heart J"},{"key":"R2-20241210","doi-asserted-by":"crossref","first-page":"e0131237","DOI":"10.1371\/journal.pone.0131237","article-title":"Prevalence and predictors of early cardiovascular events after kidney transplantation: evaluation of pre-transplant cardiovascular work-up.","volume":"10","author":"Delville","year":"2015","journal-title":"PLoS One"},{"key":"R3-20241210","doi-asserted-by":"crossref","first-page":"2946","DOI":"10.1161\/CIRCULATIONAHA.111.020982","article-title":"Chronic kidney disease is associated with the incidence of atrial fibrillation: the atherosclerosis risk in communities (ARIC) study.","volume":"123","author":"Alonso","year":"2011","journal-title":"Circulation"},{"key":"R4-20241210","doi-asserted-by":"crossref","first-page":"1330","DOI":"10.1093\/eurheartj\/ehy136","article-title":"The 2018 European Heart Rhythm Association practical guide on the use of non-vitamin K antagonist oral anticoagulants in patients with atrial fibrillation.","volume":"39","author":"Steffel","year":"2018","journal-title":"Eur Heart J"},{"key":"R5-20241210","doi-asserted-by":"crossref","first-page":"1968","DOI":"10.1182\/blood-2014-04-571232","article-title":"Direct oral anticoagulants compared with vitamin K antagonists for acute venous thromboembolism: evidence from phase 3 trials.","volume":"124","author":"van Es","year":"2014","journal-title":"Blood"},{"key":"R6-20241210","doi-asserted-by":"crossref","first-page":"955","DOI":"10.1016\/S0140-6736(13)62343-0","article-title":"Comparison of the efficacy and safety of new oral anticoagulants with warfarin in patients with atrial fibrillation: a meta-analysis of randomised trials.","volume":"383","author":"Ruff","year":"2014","journal-title":"Lancet"},{"key":"R7-20241210","doi-asserted-by":"crossref","first-page":"1139","DOI":"10.1056\/NEJMoa0905561","article-title":"Dabigatran versus warfarin in patients with atrial fibrillation.","volume":"361","author":"Connolly","year":"2009","journal-title":"N Engl J Med"},{"key":"R8-20241210","doi-asserted-by":"crossref","first-page":"883","DOI":"10.1056\/NEJMoa1009638","article-title":"Rivaroxaban versus warfarin in nonvalvular atrial fibrillation.","volume":"365","author":"Patel","year":"2011","journal-title":"N Engl J Med"},{"key":"R9-20241210","doi-asserted-by":"crossref","first-page":"981","DOI":"10.1056\/NEJMoa1107039","article-title":"Apixaban versus warfarin in patients with atrial fibrillation.","volume":"365","author":"Granger","year":"2011","journal-title":"N Engl J Med"},{"key":"R10-20241210","doi-asserted-by":"crossref","first-page":"2093","DOI":"10.1056\/NEJMoa1310907","article-title":"Edoxaban versus warfarin in patients with atrial fibrillation.","volume":"369","author":"Giugliano","year":"2013","journal-title":"N Engl J Med"},{"key":"R11-20241210","doi-asserted-by":"crossref","first-page":"566","DOI":"10.1001\/jamacardio.2017.0364","article-title":"Laboratory monitoring of non-vitamin K antagonist oral anticoagulant use in patients with atrial fibrillation: a review.","volume":"2","author":"Eikelboom","year":"2017","journal-title":"JAMA Cardiol"},{"key":"R12-20241210","doi-asserted-by":"crossref","first-page":"1","DOI":"10.2165\/0003088-200948010-00001","article-title":"Comparative pharmacodynamics and pharmacokinetics of oral direct thrombin and factor Xa inhibitors in development.","volume":"48","author":"Eriksson","year":"2009","journal-title":"Clin Pharmacokinet"},{"key":"R13-20241210","doi-asserted-by":"crossref","first-page":"705","DOI":"10.1681\/ASN.2007111207","article-title":"Dilemmas in the management of atrial fibrillation in chronic kidney disease.","volume":"20","author":"Reinecke","year":"2009","journal-title":"J Am Soc Nephrol"},{"key":"R14-20241210","doi-asserted-by":"crossref","first-page":"162","DOI":"10.1016\/j.ijcard.2016.11.303","article-title":"Non-vitamin K antagonist oral anticoagulants in atrial fibrillation patients with chronic kidney disease: a systematic review and network meta-analysis.","volume":"231","author":"And\u00f2","year":"2017","journal-title":"Int J Cardiol"},{"key":"R15-20241210","doi-asserted-by":"crossref","first-page":"451","DOI":"10.1001\/jamacardio.2016.1170","article-title":"Efficacy and safety of apixaban compared with warfarin in patients with atrial fibrillation in relation to renal function over time: insights from the ARISTOTLE randomized clinical trial.","volume":"1","author":"Hijazi","year":"2016","journal-title":"JAMA Cardiol"},{"key":"R16-20241210","doi-asserted-by":"crossref","first-page":"77","DOI":"10.1097\/FTD.0000000000000356","article-title":"Effect of the direct oral anticoagulants rivaroxaban and apixaban on the disposition of calcineurin inhibitors in transplant recipients.","volume":"39","author":"Vanhove","year":"2017","journal-title":"Ther Drug Monit"},{"key":"R18-20241210","doi-asserted-by":"crossref","first-page":"1093","DOI":"10.1378\/chest.10-0134","article-title":"A novel user-friendly score (HAS-BLED) to assess 1-year risk of major bleeding in patients with atrial fibrillation: the Euro Heart Survey.","volume":"138","author":"Pisters","year":"2010","journal-title":"Chest"},{"key":"R19-20241210","doi-asserted-by":"crossref","first-page":"263","DOI":"10.1378\/chest.09-1584","article-title":"Refining clinical risk stratification for predicting stroke and thromboembolism in atrial fibrillation using a novel risk factor-based approach: the Euro Heart Survey on atrial fibrillation.","volume":"137","author":"Lip","year":"2010","journal-title":"Chest"},{"key":"R20-20241210","doi-asserted-by":"crossref","first-page":"150","DOI":"10.1016\/j.jpba.2013.02.007","article-title":"Rapid determination of apixaban concentration in human plasma by liquid chromatography\/tandem mass spectrometry: application to pharmacokinetic study.","volume":"78\u201379","author":"Delavenne","year":"2013","journal-title":"J Pharm Biomed Anal"},{"key":"R21-20241210","doi-asserted-by":"crossref","first-page":"126","DOI":"10.1016\/j.thromres.2017.09.001","article-title":"Evaluation of dabigatran, rivaroxaban and apixaban target-specific assays in a multicenter French study.","volume":"158","author":"Gouin-Thibault","year":"2017","journal-title":"Thromb Res"},{"key":"R22-20241210","doi-asserted-by":"crossref","first-page":"692","DOI":"10.1111\/j.1538-7836.2005.01204.x","article-title":"Definition of major bleeding in clinical investigations of antihemostatic medicinal products in non-surgical patients.","volume":"3","author":"Schulman","year":"2005","journal-title":"J Thromb Haemost"},{"key":"R23-20241210","doi-asserted-by":"crossref","first-page":"1676","DOI":"10.1161\/STROKEAHA.111.000402","article-title":"Cost-effectiveness of apixaban, dabigatran, rivaroxaban, and warfarin for stroke prevention in atrial fibrillation.","volume":"44","author":"Harrington","year":"2013","journal-title":"Stroke"},{"key":"R24-20241210","doi-asserted-by":"crossref","first-page":"73","DOI":"10.1159\/000371902","article-title":"Risk of major hemorrhage after kidney transplantation.","volume":"41","author":"Sood","year":"2015","journal-title":"Am J Nephrol"},{"key":"R25-20241210","doi-asserted-by":"crossref","first-page":"3013","DOI":"10.1016\/j.transproceed.2011.07.018","article-title":"Risk factors for early hemorrhagic and thrombotic complications after kidney transplantation.","volume":"43","author":"Pawlicki","year":"2011","journal-title":"Transplant Proc"},{"key":"R26-20241210","doi-asserted-by":"crossref","first-page":"833","DOI":"10.1111\/jth.13985","article-title":"Variation of renal function over time is associated with major bleeding in patients treated with direct oral anticoagulants for atrial fibrillation.","volume":"16","author":"Becattini","year":"2018","journal-title":"J Thromb Haemost"},{"key":"R27-20241210","doi-asserted-by":"crossref","first-page":"1514","DOI":"10.1111\/j.1600-6143.2004.00539.x","article-title":"CYP3A4 and P-glycoprotein activity in healthy controls and transplant patients on cyclosporin vs. tacrolimus vs. sirolimus.","volume":"4","author":"Lemahieu","year":"2004","journal-title":"Am J Transplant"},{"key":"R28-20241210","doi-asserted-by":"crossref","first-page":"655","DOI":"10.1124\/dmd.111.043018","article-title":"Cyclosporine A- and tacrolimus-mediated inhibition of CYP3A4 and CYP3A5 in vitro.","volume":"40","author":"Amundsen","year":"2012","journal-title":"Drug Metab Dispos"},{"key":"R29-20241210","doi-asserted-by":"crossref","first-page":"e12","DOI":"10.1097\/TP.0000000000000223","article-title":"Increased levels of rivaroxaban in patients after liver transplantation treated with cyclosporine A.","volume":"98","author":"Wannhoff","year":"2014","journal-title":"Transplantation"}],"container-title":["Transplantation"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/journals.lww.com\/10.1097\/TP.0000000000003168","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,12,10]],"date-time":"2024-12-10T17:28:34Z","timestamp":1733851714000},"score":1,"resource":{"primary":{"URL":"https:\/\/journals.lww.com\/10.1097\/TP.0000000000003168"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2020,2,10]]},"references-count":28,"journal-issue":{"issue":"12","published-print":{"date-parts":[[2020]]}},"URL":"https:\/\/doi.org\/10.1097\/tp.0000000000003168","relation":{},"ISSN":["0041-1337"],"issn-type":[{"value":"0041-1337","type":"print"}],"subject":[],"published":{"date-parts":[[2020,2,10]]}}}